Novartis Ritalin LA clears FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis adds second once-daily methylphenidate product with the June 5 approval of Ritalin LA, to be launched by the beginning of the 2002-2003 school year. The drug, developed using Elan's Spheroidal Oral Drug Absorption System (SODAS), has a bi-modal release, with half the dose in immediate-release beads and half in delayed-release beads that provide methylphenidate four hours later. Ritalin SR, in contrast, provides continuous drug release over eight hours. Ritalin LA will be available in 20 mg, 30 mg and 40 mg capsules that can be sprinkled onto applesauce, while Ritalin SR is available in 20 mg tablet
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.